Prolactin in autoimmunity and antitumor defence

Journal of Neuroimmunology

Volumn 109, Issue 1, 2000, Pages 47-55

  Matera, Lina ^a   Mori, Marcella ^a   Geuna, Massimo ^b   Buttiglieri, Stefano ^a   Palestro, Giorgio ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b Institute of Cancer Research and Treatment   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Antitumour lymphocytes; Autoimmunity; Prolactin; Th1 Th2 cytokines

Indexed keywords

BROMOCRIPTINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; PROLACTIN;

ANIMAL MODEL; ARTICLE; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; CANCER CONTROL; CANCER GROWTH; EXPERIMENTAL MODEL; GRAFT REJECTION; HUMAN; HYPERPROLACTINEMIA; IMMUNE RESPONSE; LYMPHOCYTE; MOUSE; NEUROENDOCRINOLOGY; NEUROIMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; CYTOKINES; HUMANS; NEOPLASMS; NEUROSECRETORY SYSTEMS; PROLACTIN; TH1 CELLS; TH2 CELLS;

EID: 0034284078     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00302-7     Document Type: Article

References (60)

1. Ader R., Cohen N., Felten D. Psychoneuroimmunology: interaction between the nervous system and the immune system. Lancet. 345:1995;99-103.
2. Alvarez-Nemegyei J., Cobarrubias-Cobos A., Escalante-Triay F., Sosa-Munoz J., Miranda J.M., Jara L.J. Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Lupus. 7:1998;414-419.
3. Azar S.T., Yamout B. Prolactin secretion is increased in patients with multiple sclerosis. Endocrine Res. 25:1999;207-214.
4. Bazan J.F. A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain. Biochem. Biophys. Res. Commun. 164:1989;788-795.
5. Bellone G., Geuna M., Carbone A., Silvestri S., Foa R., Emanuelli G., Matera L. Regulatory action of prolactin on the in vitro growth of CD34+ve human hemopoietic progenitor cells. J. Cell. Physiol. 163:1995;221-231.
6. Ben-Jonathan M., Mershon J.L., Allen D.L., Steinmetz R.W. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocrine Rev. 17:1996;639-668.
7. Bernton E.W., Beach J.E., Holaday J.W., Smallridge R.C., Fein H.G. Release of multiple hormones by a direct action of interleukin-1 in pituitary cells. Science. 238:1987;519-521.
8. Besedovsky H.O., Sorkin E., Keller M., Muller J. Changes in blood hormone levels during the immune response. Proc. Soc. Exp. Biol. Med. 150:1985;466-471.
9. Besedovsky O.H., Del Rey A. Immune-neuro-endocrine interaction: facts and hypothesis. Endocrine Rev. 17:1996;64-102.
10. Bindoni M., Belluardo N., Licciarello S., Marchese A.E., Cicirata F. Growth of Yoshida ascite tumor in rat after radiofrequency destruction of the tuberinfundibolar region of the hypothalamus. Neuroendocrinology. 30:1980;88-94.
11. Carrier M., Emery R.W., Wild-Mobley J., Perrotta N.J., Russell D.H., Copeland J.G. Prolactin as a marker of rejection in human heart transplantation. Transplant Proc. 19:1987;3442-3443.
12. Cella M., Sallusto F., Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9:1997;10-16.
13. Cesano A., Oberholtzer E., Contarini M., Geuna M., Bellone G., Matera L. Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors. Immunopharmacology. 28:1994;67-75.
14. Chakraborty A., Chakraborty N.G., Chattopadhyay U. Prolactin response of NK cells, but not of LAK cells, is deficient in patients with carcinoma of oral cavity and during aging. Int. J. Cancer. 66:1996;65-69.
15. Chicanza I.C., Petrou P., Charousos G., Kingsley G., Panay G.S. Excessive and disregulated secretion of prolactin in rheumatoid arthritis: immunopathogenetic and therapeutic implication. Br. J. Rheumatol. 32:1993;445-448.
16. Chikanza I.C. Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann. NY Acad. Sci. 876:1999;119-130.
17. Clapp C., Martial J.A., Guzman R.C., Rentier-Delure F., Weiner R.I. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology. 133:1993;1292-1299.
18. Cosman D. The hematopoietin receptor superfamily. Cytokine. 5:1993;95-106.
19. Cross R.J., Markesbery W.R., Bruks W.H., Rozman T.L. Immunology. 51:1984;399-416.
20. Dallman M.J. Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult. Curr. Opin. Immunol. 7:1995;632-638.
21. Dijkstra C.D., Van der Voort E.R., De Groot C.J., Huitinga I., Uitdehaag B.M., Polman C.H., Berkenbosch F. Therapeutic effect of the D2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis. Psychoneuroendocrinology. 19:1994;135-142.
22. Duncan G.S., Mattrucker H.W., Kagi D., Matsuyama T., Mak T.W. The transcription factor interferon regulatory factor-1 is essential for natural killer cell function in vivo. J. Exp. Med. 184:1996;2043-2048.
23. Elbourne K.B., Keisler D., McMurray R.W. Differential effects of estrogen and prolactin on autoimmune disease in the NZB/NZW F1 mouse model of systemic lupus erythematosus. Lupus. 7:1998;420-427.
24. Forni G., Bindoni M., Santoni A., Belluardo N., Marchese A.E., Giovarelli M. Radiofrequency destruction of the tuberoinfundibolar region of the hypothalamus permanently abrogates NK cell activity in mice, 1983. Nature. 306:1983;181-186.
25. Gaidano G., Contarini M., Pastore C., Saglio G., Matera L. AIDS-related Burkitt's-type lymphomas are a target for lymphokine-activated killers induced by interleukin-2 and prolactin. Proc. Soc. Exp. Biol. Med. 213:1996;196-205.
26. Grewe M., Bruijnzeel-Koomen C.A., Schopf E., Thepen T., Langeveld-Wildschut A.G., Ruzicka T., Krutmann J. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol. Today. 19:1998;359-361.
27. Hiestand P.C., Gale J.M., Mekler P., Soft O. Soft immunosuppression by inhibition of prolactin release: synergism with cyclosporine in kidney allograft survival and in the localized graft-versus-host reaction. Transplant. Proc. 18:1986;870-872.
28. Horseman N.D., Yu-Lee L.Y. Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin, and hematopoietic cytokines. Endocrine Rev. 15:1994;627-649.
29. Jung T., Moessner R., Dieckhoff K., Heidrich S., Neumann C. Mechanism of deficient IFNγ in atopic disease. Clin. Exp. Allergy. 29:1999;912-919.
30. Kalinski P., Hilknes C.M.U., Wierfenga E.A., Kapssenberg M.L. T-cell priming by type-I and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today. 20:1999;561-567.
31. Kooijman R., Hooghe Peters E.L., Hooghe R. Prolactin, growth hormone and insulin-like growth factor-1 in the immune system. Adv. Neuroimmunol. 63:1996;377-454.
32. Krumenacker J.S., Montgomery D.W., Bucklye D.J., Gout P.W., Buckley A.R. Prolactin receptor signaling: shared components with the T-cell antigen receptor in Nb2 lymphoma cells. Endocrine. 9:1998;313-320.
33. Larson D.F., Copland J.G., Russell D.H. Prolactin predicts cardiac allograft rejection in cyclosporin immunosuppressed patients. Lancet. 2:1985;53.
34. MacDonalds K.P., Nishioka Y., Lipsky P.E., Thomas R. Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J. Clin. Invest. 100:1997;2404-2414.
35. Majewski S., Marczak M., Szmurlo A., Jablonska S., Bollag W.J. Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. Invest. Dermatol. 106:1996;1114-1118.
36. Matera L. Action of pituitary and lymphocyte prolactin. Neuroimmunomodulation. 4:1997;171-180.
37. Matera L., Cutufia M., Geuna M., Contarini M., Buttiglieri S., Galin S., Fazzari A., Cavaliere C. Prolactin is an autocrine growth factor for the Jurkat human T-leukemic cell line. J. Neuroimmunol. 79:1997;12-21.
38. Matera L., Contarini M., Bellone G., Forno B., Biglino A. Up-modulation of interferon-γ mediates the enhancement of spontaneous cytotoxicity in prolactin-activated natural killer cells. Immunology. 98:1999;386-392.
39. Matera L., Galetto A., Geuna M., Vekemans K., Ricotti E., Contarini M., Moro F. Individual and combined effect of granulocyte-macrophage colony-stimulating factor and prolactin on maturation of dendritic cells from blood monocytes under serum-free conditions. Immunology. 99:2000;1-9.
40. Matera, L., Mori, M., 2000b. Different cooperation of PRL with IL-2 and IL-12 on production of IFNγ by NK and T cells. Ann. NY Acad. Sci., in press.
41. Matera L., Geuna M., Pastore C., Buttiglieri S., Gaidano G., Savarino A., Marengo S., Vonderhaar K. Expression of prolactin and prolactin receptors by non-Hodgkin's lymphoma cells. Int. J. Cancer. 85:2000;124-130.
42. McMurray R.W., Allen S.H., Pepmueller P.H., Keisler D., Cassisy J.T. Elevated serum prolactin levels in children with juvenile rheumatoid and antinuclear antibody seropositivity. J. Rheumatol. 22:1995;1577-1580.
43. Mosmann T.R., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today. 17:1996;138-146.
44. Nagafuchi H., Suzuki N., Kaneko A., Asai T., Sakane T.J. Prolactin locally produced by synovium infiltrating T lymphocytes induces excessive synovial cell functions in patients with rheumatoid arthritis. Rheumatology. 26:1999;1890-1900.
45. Nagy E., Berczi I. Hypophysectmized rats depend on residual prolactin for survival. Endocrinology. 128:1991;2776-2784.
46. Nakajima A., Hirose S., Yagita H., Okumura K. Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice. J. Immunol. 158:1997;1466-1472.
47. Oberholtzer E., Contarini M., Veglia F., Cossarizza A., Franceschi C., Geuna M., Provinciali M., Di Stefano G., Sissom J., Brizzi M.F., Pegoraro L., Matera L. Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors. Adv. Neuroimmunol. 6:1996;233-247.
48. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity. 8:1998;275-283.
49. O'Garra A., Murphy K. T-cell subsets in autoimmunity. Curr. Opin. Immunol. 5:1993;880-886.
50. Peng S.L., Moslehi J., Craft J. Roles of interferon-gamma and interleukin-4 in murine lupus. J. Clin. Invest. 99:1997;1936-1946.
51. Romagnani S. Biology of human Th1 and Th2 cells. J. Clin. Immunol. 15:1995;121-129.
52. Russell D.H., Mills K.T., Talamantes F.J., Bern H.A. Neonatal administration of prolactin antiserum alters the developmental pattern of T- and B-lymphocytes in the thymus and spleen of BALB/C female mice. Proc. Natl. Acad. Sci. 85:1988;7404-7407.
53. Shurin M.R., Lu L., Kalinski P., Stewart-Akers A.M., Lotze M.T. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Sem. Immunopathol. 21:1999;339-359.
54. Suthantiran M., Strom T.B. Immunobiology and immunopharmacology of organ allograft rejection. J. Clin. Immunol. 15:1995;161-171.
55. Thomas R., Quinn C. Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium. J. Immunol. 156:1996;3074-3086.
56. Tokano Y., Morimoto S., Kaneko H., Amano H., Nozawa K., Takasaki Y., Hashimoto H. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE) - relation to Th1- and Th2-derived cytokines. Clin. Exp. Immunol. 116:1999;169-173.
57. Walker S., Allen S.H., Hoffman R.W., McMurray R. Prolactin: a stimulator of disease activity in systemic lupus erythematosus. Lupus. 4:1995;3-9.
58. Wilder R.L. Hormones, pregnancy, and autoimmune diseases. Ann. NY Acad. Sci. 840:1998;45-50.
59. Yu M., Johnson J.M., Tuohy V.K. Generation of autonomously pathogenic neoautoreactive TH1 cells during the development of the determinant spreading cascade in murine autoimmune encephalomyelitis. J. Neurosci. 45:1996;463-470.
60. Yu-Lee L.Y. Molecular actions of prolactin in the immune system. Proc. Soc. Exp. Biol. Med. 215:1997;35-52.